Why the study?
Does systemic doxorubicin administration cause muscle weakness and fatigue through TNFR1 in a murine model?
Does systemic doxorubicin administration cause muscle weakness and fatigue through TNFR1 in a murine model?
Systemic doxorubicin causes skeletal muscle weakness in mice through a TNFR1-dependent mechanism, suggesting a potential pathway for chemotherapy-induced fatigue.
Answers are grounded in this paper and cite their sources.
TNFR1 mediates doxorubicin-induced EDL weakness in mice; hypothesis-generating for chemotherapy-related fatigue, with no clinical implications yet.
Cancer patients receiving doxorubicin chemotherapy experience both muscle weakness and fatigue. One postulated mediator of the muscle dysfunction is an increase in tumor necrosis factor-alpha (TNF), a proinflammatory cytokine that mediates limb muscle contractile dysfunction through the TNF receptor subtype 1 (TNFR1). Our main hypothesis was that systemic doxorubicin administration would cause muscle weakness and fatigue. Systemic doxorubicin administration (20 mg/kg) depressed maximal force of the extensor digitorum longus (EDL; P < 0.01), accelerated EDL fatigue (P < 0.01), and elevated serum TNF levels (P < 0.05) 72 h postinjection. Genetic TNFR1 deficiency prevented the fall in specific force caused by systemic doxorubicin, without protecting against fatigue (P < 0.01). These results demonstrate that clinical doxorubicin concentrations disrupt limb muscle function in a TNFR1-dependent manner.
No takes yet. Share an insight, caveat, or question.
Gilliam et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: